Skip to main content

Wilson's Disease

1
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Vivet Therapeutics
Vivet TherapeuticsFrance - Paris
1 program
1
VTX-801Phase 1/21 trial
Active Trials
NCT04537377Active Not Recruiting4Est. Jun 2029
Orphalan
OrphalanFrance - Paris
3 programs
International Wilson's Disease Patient Registry (iWilson Registry)N/A1 trial
900mg TETA 4HCl Once Daily FormulationPHASE_11 trial
New TETA 4HCl FormulationPHASE_21 trial
Active Trials
NCT05239858Recruiting500Est. Dec 2027
NCT06128954Completed26Est. Feb 2024
NCT07010575Completed10Est. Dec 2025
Ergomed
ErgomedUK - Guildford
1 program
International Wilson's Disease Patient Registry (iWilson Registry)N/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
OrphalanNew TETA 4HCl Formulation
Vivet TherapeuticsVTX-801
Orphalan900mg TETA 4HCl Once Daily Formulation
OrphalanInternational Wilson's Disease Patient Registry (iWilson Registry)

Clinical Trials (4)

Total enrollment: 540 patients across 4 trials

NCT07010575OrphalanNew TETA 4HCl Formulation

Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride

Start: Jul 2025Est. completion: Dec 202510 patients
Phase 2Completed
NCT04537377Vivet TherapeuticsVTX-801

A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease

Start: Sep 2021Est. completion: Jun 20294 patients
Phase 1/2Active Not Recruiting
NCT06128954Orphalan900mg TETA 4HCl Once Daily Formulation

Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily).

Start: Jan 2024Est. completion: Feb 202426 patients
Phase 1Completed
NCT05239858OrphalanInternational Wilson's Disease Patient Registry (iWilson Registry)

International Wilson's Disease Patient Registry (iWilson Registry)

Start: Jun 2022Est. completion: Dec 2027500 patients
N/ARecruiting

Related Jobs

Senior Director, Global Distribution Quality

Ultragenyx PharmaceuticalUltragenyx Pharmaceutical
Bedford, MA; Novato, CA
1mo ago
$251K - $311K/yr

Intern, Environmental Health and Safety

Ultragenyx PharmaceuticalUltragenyx Pharmaceutical
Bedford, MA
1mo ago
$23 - $30/hr

Intern, Maintenance Coordinator

Ultragenyx PharmaceuticalUltragenyx Pharmaceutical
Bedford, MA
1mo ago
$48K - $52K/yr

Facilities Technician II (GMP) – Pitman Schedule (12:00 AM–10:00 AM)

Ultragenyx PharmaceuticalUltragenyx Pharmaceutical
Bedford, MA
1mo ago
From $64K/yr

Medical Science Liaison

Ultragenyx PharmaceuticalUltragenyx Pharmaceutical
Japan
2mo ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 540 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.